How do we measure OPD ROI and monetize the advanced diagnostic test regimen?

Question 7: How do we measure OPD ROI and monetize the advanced diagnostic test regimen?

From the Marco Power Forum III, New Orleans, LA

with:
Larry Patterson, MD
Mitch Jackson, MD
Cynthia Matossian, MD
Neda Shamie, MD
Toby Tyson, MD


Thanks to Marco for letting me re-post this; I realize the panel and the video was aimed at OMDs primarily, but so much of the discussion is highly relevant to ODs. -- adam

-----
Other videos from the Power Forum III:

Question 1: How does data from Angles Alpha & Kappa, Corneal SA, Coma, pupil size, and Corneal vs. Lenticular Astigmatism improve your premium IOL selections and outcomes?

Question 2: What wavefront data should you use to select EDOF IOLs for patients?

Question 3: What are the multi-function benefits of using an integrated Wavefront Aberrometer, registered on the patient’s optical center?

Question 4: When OSD is discovered prior to surgery, should you postpone the procedure for treatment, or stabilize the tear film, then proceed with surgery?

Question 5: How do we characterize and localize Astigmatisms within the optical pathway?

Question 6: How do you manage patient expectations and IOL selection?

Question 7: How do we measure OPD ROI and monetize the advanced diagnostic test regimen?